<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepat Mon</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>Hepatitis Monthly</journal-title></journal-title-group><issn pub-type="ppub">1735-143X</issn><issn pub-type="epub">1735-3408</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22312397</article-id><article-id pub-id-type="pmc">3271324</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Induced HBs antigenemia in healthy adults after immunization with two different hepatitis B recombinant vaccines</article-title><alt-title alt-title-type="short">HBs antigenemia after hepatitis B vaccination</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ziaee</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sa&#x000e1;datjoo</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mohamadpour</surname><given-names>Malihe</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Namaei</surname><given-names>Mohammad Hasan</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="corresp" rid="COR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Infectious Disease Ward, Birjand University of Medical Sciences, Birjand, IR Iran</aff><aff id="A2"><label>2</label>Birjand University of Medical Sciences, Birjand, IR Iran</aff><aff id="A3"><label>3</label>Bahar Rehabilitation Institute, Birjand, IR Iran</aff><aff id="A4"><label>4</label>Birjand University of Medical Sciences, Birjand, IR Iran</aff><author-notes><corresp id="COR1"><label>*</label>Corresponding author at: Dr. Mohammad Hasan Namaei, Assistant Professor, Faculty of Medicine, Ghafary Ave., Birjand, South Khorasan, IR Iran. Tel.: +98-9151612148, Fax: +98-9151612148, E-mail: <email>mhnamaei@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Autumn</season><year>2010</year></pub-date><pub-date pub-type="epub"><day>01</day><month>12</month><year>2010</year></pub-date><volume>10</volume><issue>4</issue><fpage>298</fpage><lpage>301</lpage><history><date date-type="received"><day>02</day><month>1</month><year>2010</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2010</year></date><date date-type="rev-recd"><day>27</day><month>8</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011, Kowsar M.P. Co.</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract abstract-type="executive-summary"><sec id="st1"><title>Background and Aims</title><p>Currently, vaccination is the most effective protective tool against hepatitis B virus infection. Some studies have shown that positive results for a hepatitis B virus surface antigen (HBsAg) test may be seen after vaccination.</p></sec><sec id="st2"><title>Materials and Methods</title><p>In this clinical trial study, 62 healthy adult volunteers were randomly assigned to receive either the Engerix-B or the Hepavax-Gene hepatitis B recombinant vaccine. Blood samples were drawn 1, 3, and 5 days after vaccination and were tested for HBsAg using two different ELISA kits (Behring and Mega).</p></sec><sec id="st3"><title>Results</title><p>HBsAg was positive in 5, 3, and 2 participants of the Engerix-B group in the 1st, 3rd, and 5th days after vaccination, respectively, using the Behring ELISA kit the test was positive in only one subject in the Hepavax-Gene group, on the 5th day after vaccination. No positive result was seen in any groups when the Mega ELISA kit was used to test the specimens.</p></sec><sec id="st4"><title>Conclusions</title><p>Our results showed transient HBsAg antigenemia after vaccination against hepatitis B. This condition depends on the type of vaccine and the HBsAg diagnostic test.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Hepatitis B vaccine</kwd><kwd>Hepatitis B Surface Antigens</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Hepatitis B, the most serious type of viral hepatitis, is a major health problem throughout the world. According to a WHO report, around 2 billion people are infected with the hepatitis B virus (HBV) in the world, and about 600,000 people die annually due to its acute or chronic consequences. There are more than 350 million HBV carriers in the world [<xref ref-type="bibr" rid="R1">1</xref>]. People who are in continuous contact with blood and bodily fluids are the most likely to contract hepatitis B. High-risk populations include dialysis patients, health-care workers, infants born to mothers infected with HBV, and intravenous drug abusers [<xref ref-type="bibr" rid="R2">2</xref>].Vaccination against hepatitis B plays an important role in the prevention of HBV infection in high-risk population. An effective vaccination can prevent HBV infection in 95% of immunized individuals as well as the hepatocellular carcinoma in the children of chronic HBV infection [<xref ref-type="bibr" rid="R3">3</xref>].A predictable group for hepatitis B contamination as high-risk population was the first target for vaccination in the United States after the first development of hepatitis vaccine in 1981. In contrast, the vaccine was not very successful and the rate of hepatitis B continued to grow. Therefore, in 1991 the Centers for Disease Control suggested vaccination for both high-risk adolescents and all newborns, and subsequently the international recommendation (by WHO) was to vaccinate all infants against hepatitis B by 1997 [<xref ref-type="bibr" rid="R4">4</xref>]. This strategy led to a decrease in the incidence of hepatitis B worldwide [<xref ref-type="bibr" rid="R3">3</xref>][<xref ref-type="bibr" rid="R5">5</xref>][<xref ref-type="bibr" rid="R6">6</xref>].Some studies have reported positive results of HBsAg tests after hepatitis B immunization in infants [<xref ref-type="bibr" rid="R7">7</xref>][<xref ref-type="bibr" rid="R8">8</xref>][<xref ref-type="bibr" rid="R9">9</xref>] as well as adolescents [<xref ref-type="bibr" rid="R5">5</xref>][<xref ref-type="bibr" rid="R10">10</xref>][<xref ref-type="bibr" rid="R11">11</xref>]. False positive HBsAg results after vaccination can lead to the misdiagnosis of being infected with hepatitis B for healthy individuals, causing unnecessary concern and treatments. A careful diagnosis of HBV is even more important in blood donors. Dow et al. [<xref ref-type="bibr" rid="R12">12</xref>] showed that hepatitis B vaccination can lead to a misdiagnosis in blood donors in the week after vaccination. Otag [<xref ref-type="bibr" rid="R11">11</xref>] Emphasizes that the period of antigenemia could extend for up to one month.The aim of this study was to compare the incidence of positive results of HBsAg tests after vaccination with two different hepatitis B recombinant vaccines.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><p>This clinical trial study was conducted on 62 healthy medical students who were at the beginning of their clinical courses and needed to be vaccinated against HBV. They were between 20 and 22 years old and tested negative for HBc antibody and had no history of HBV vaccination, jaundice, or blood or blood-derived-products transfusion during the past 3 months. The study protocol was approved by the research ethics committee of the Birjand University of Medical Sciences, and all participants signed an informed-consent form for participation. Subjects were assigned into two vaccination groups by simple randomization. The two types of vaccines were Hepavax-Gene (manufactured by Green Cross Vaccine Corp., Seoul, Korea) and Engerix-B (manufactured by GlaxoSmithKline, Rixensart, Belgium). There were 32 and 30 subjects in the Hepavax-Gene and Engerix-B groups, respectively. A full dose of vaccine was administrated intramuscularly for all subjects as the first dose of vaccination against HBV. All subjects were vaccinated 1 and 6 months after the first vaccination. Blood samples were drawn 1, 3, and 5 days after the first dose of vaccination and tested for HBsAg by two different ELISA kits (Behring, Marburg, Germany; and Mega, Los Angeles, California, USA). All tests were performed by one person in the same setting. The immunization status of all participants was evaluated 3 months after vaccination by testing for HBsAb using Behring (Marburg, Germany) anti-HBs ELISA kits. The results are expressed as mean &#x000b1; standard deviation (SD) for quantitative variables and percentages for categorical variables. Categorical variables were compared with a Fisher exact test. P values of 0.05 or less were considered statistically significant. All statistical analyses were performed using SPSS version 15.</p></sec><sec id="s3"><title>Results</title><p>Of the 62 participants, 36 (58.1%) were female. Half of the women were in the Engerix-B group and half were in the Hepavax-Gene group. Positive results for the HBsAg test in the 1st, 3rd, and 5th day after vaccination with the two types of vaccines were different when the Behring ELISA kit was used. In the Engerix-B group, 5 (16.7%), 3 (10%), and 2 (6.7%) people had positive results 1, 3, and 5 days after vaccination, respectively (<xref ref-type="table" rid="s3tbl1">Table 1</xref>). In the Hepavax-Gene group, no one had positive results in Days 1 and 3, and only 1 (3.1%) person tested positive 5 days after vaccination. There was a statistically significant differences between the two vaccination groups in the prevalence of false positive results of HBsAg on day 1 (<xref ref-type="table" rid="s3tbl2">Table 2</xref>).</p><p>No positive results were observed in any person in either vaccination group when the Mega ELISA kit was used to test for HBsAg in the blood specimens.All subjects were tested for HBsAb 3 months after completing their vaccination. Additionally, all individuals in both groups had a protective antibody level of more than 10 IU/ml.</p><table-wrap id="s3tbl1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Result summary of subjects with false positive results of hepatitis B surface antigen test</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"><bold>Vaccine type</bold></td><td rowspan="1" colspan="1"><bold>Patient No.</bold></td><td rowspan="1" colspan="1"><bold>Age</bold></td><td rowspan="1" colspan="1"><bold>Sex</bold></td><td rowspan="1" colspan="1"><bold>Days after Vaccination</bold></td><td rowspan="1" colspan="1"><bold>HBsAg Test</bold></td></tr></thead><tbody><tr><td rowspan="24" colspan="1">Engerix-B</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">female</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">female</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">female</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">male</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">male</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">male</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">male</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">female</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Positive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="3" colspan="1">Hepavax-Gene</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">male</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Positive</td></tr></tbody></table></table-wrap><table-wrap id="s3tbl2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Comparison of the incidence of HBsAg false positive results between the two vaccine groups during the first 5 days after vaccination</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="2" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><bold>Vaccine group <xref ref-type="table-fn" rid="Fs3tbl2a">a</xref></bold></td><td rowspan="2" colspan="1"><bold>p-Value</bold></td></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Hapavax-Gene(No.=32)</bold></td><td rowspan="1" colspan="1"><bold>Engerix-B (No.=30)</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>After 1 day</bold></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">5 (16.7%)</td><td rowspan="1" colspan="1">0.02 <xref ref-type="table-fn" rid="Fs3tbl2b">b</xref></td></tr><tr><td rowspan="1" colspan="1"><bold>After3 day</bold></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (10%)</td><td rowspan="1" colspan="1">0.07</td></tr><tr><td rowspan="1" colspan="1"><bold>After5 day</bold></td><td rowspan="1" colspan="1">1 (3.1%)</td><td rowspan="1" colspan="1">2 (6.7%)</td><td rowspan="1" colspan="1">0.52</td></tr></tbody></table><table-wrap-foot><fn id="Fs3tbl2a"><p><sup>a</sup> Number of individuals with a positive result on the HBsAg test (percentage of N)</p></fn><fn id="Fs3tbl2b"><p><sup>b</sup> Differences between the two groups were statistically significant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4"><title>Discussion</title><p>HBsAg is the most common serological marker for the diagnosis of hepatitis B. Contrary to recent studies [<xref ref-type="bibr" rid="R11">11</xref>][<xref ref-type="bibr" rid="R12">12</xref>], primary research after the development of plasma-derived HBV vaccine did not reveal postvaccination HBs antigenemia [<xref ref-type="bibr" rid="R13">13</xref>]. Our study showed transient HBs antigenemia after administration of vaccinating against hepatitis B. The results of this study showed that different types of hepatitis B vaccines can result in different rates of false positive results for an HBsAg test. As shown in table 1, in the Engerix-B group, 8 (26%) people tested positive for HBsAg during 5 days after vaccination, but Hepavax-Gene caused antigenemia in only 1 subject (3.1%). In a similar study, Otag [<xref ref-type="bibr" rid="R11">11</xref>] found different rates of HBs antigenemia caused by different hepatitis B vaccines as well, but because the sample size of her study was low, she was not able to perform any statistical analysis.Our results indicate that different HBsAg ELISA kits detect antigenemia differently. In this study, the Behring ELISA kit found 8 (26.7%) false positive HBsAg cases in the Engerix-B group, whereas the Mega ELISA kit did not detect any antigenemia. Dow et al. [<xref ref-type="bibr" rid="R12">12</xref>] used 3 different HBsAg assays with 8 volunteers to test antigenemia in the days after immunization. Similar to our study, there were differences between the results of the HBsAg assays. Of the 8 HBsAg-positive subjects in the Engerix-B group, the development of antigenemia occurred at different periods of time. Specifically, 5, 1, and 2 participants developed antigenemia at 1, 3, and 5 days after vaccination, respectively. There was one positive antigenemia in the Hepavax-Gene group, which was found on Day 5. Some studies have reported different times for the onset of antigenemia [<xref ref-type="bibr" rid="R14">14</xref>]. Based on the results, all subjects with an onset of antigenemia in the first 3 days after vaccination had a negative HBsAg result on Day 5. The clearance period (i.e., the time between the appearance of HBsAg and when it is undetectable) in our study ranged between 2 and 4 days. In Otag's study, antigenemia disappeared within 3 days [<xref ref-type="bibr" rid="R11">11</xref>]. Some studies have reported prolonged antigenemia in neonates or hemodialysis patients, even after several weeks [<xref ref-type="bibr" rid="R9">9</xref>][<xref ref-type="bibr" rid="R15">15</xref>]. In our study, there was no difference in the acquisition of immunity between the Engerix-B and Hepavax-Gene groups after 3 months of follow-up.</p></sec><sec id="s6"><title>Conclusion</title><p>Our results indicate that HBs antigenemia may occur after vaccination against hepatitis B. This positive HBsAg result can vary by the type of vaccine or across different HBsAg ELISA kits. Therefore, health-care workers should be informed about possible HBs antigenemia after vaccination against hepatitis B. Still, there is no difference in immunization between subjects with and without false positive HBsAg results.</p></sec></body><back><ack><p>This research was founded by Research Affairs at the Birjand University of Medical Sciences. The authors would like to thank Mr. M. Khorashadizade and Mr. A. Eftekhari for their laboratory assistance and the vice chancellor for research affairs at the Birjand University of Medical Sciences for financial support.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>WHO.</surname><given-names/></name></person-group><source>World Health Organization (WHO): Hepatitis B Fact Sheet No. 204</source><year>2008</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization.</publisher-name><comment>[updated 2008; cited]; Available from:<ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs204/en/">http://www.who.int/mediacentre/factsheets/fs204/en/</ext-link></comment></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisberg</surname><given-names>SS</given-names></name></person-group><article-title>Vaccine preventable diseases: current perspectives in historical context, Part I</article-title><source>Dis Mon</source><year>2007</year><volume>53</volume><issue>9</issue><fpage>422</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">17996745</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MH</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Lai</surname><given-names>MS</given-names></name><name><surname>Hsu</surname><given-names>HM</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Kong</surname><given-names>MS</given-names></name><name><surname>Liang</surname><given-names>DC</given-names></name><name><surname>Shau</surname><given-names>WY</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name></person-group><article-title>Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><issue>26</issue><fpage>1855</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9197213</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><article-title>MMWR Morb Mortal Wkly Rep, Global progress toward universal childhood hepatitis B vaccination, 2003; 2003 Sep 12</article-title><source>Report No.: 1545-861X (Electronic) 0149-2195 (Linking) Contract No.: Document Number|</source><pub-id pub-id-type="pmid">12970620</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>D</given-names></name><name><surname>Yee</surname><given-names>HF Jr</given-names></name><name><surname>Brezina</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Gitnick</surname><given-names>G</given-names></name><name><surname>Saab</surname><given-names>S</given-names></name></person-group><article-title>Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization</article-title><source>Am J Gastroenterol</source><year>2002</year><volume>97</volume><issue>1</issue><fpage>138</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11808938</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MH</given-names></name></person-group><article-title>Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations</article-title><source>J Clin Virol</source><year>2006</year><volume>36 Suppl 1</volume><fpage>S45</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16831693</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>Z</given-names></name><name><surname>Khamaysi</surname><given-names>N</given-names></name><name><surname>Elena</surname><given-names>H</given-names></name><name><surname>Gershtein</surname><given-names>V</given-names></name><name><surname>Orenstein</surname><given-names>L</given-names></name><name><surname>Lahat</surname><given-names>N</given-names></name></person-group><article-title>Transient surface antigenemia in newborn infants vaccinated with Engerix B: occurrence and duration</article-title><source>Pediatr Infect Dis J</source><year>1994</year><volume>13</volume><issue>10</issue><fpage>931</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7854896</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>SR</given-names></name><name><surname>Krieger</surname><given-names>P</given-names></name><name><surname>Puppala</surname><given-names>BL</given-names></name><name><surname>Costello</surname><given-names>M</given-names></name></person-group><article-title>Incidence and duration of hepatitis B surface antigenemia after neonatal hepatitis B immunization</article-title><source>J Pediatr</source><year>1994</year><volume>125</volume><issue>4</issue><fpage>621</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">7931886</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koksal</surname><given-names>N</given-names></name><name><surname>Altinkaya</surname><given-names>N</given-names></name><name><surname>Perk</surname><given-names>Y</given-names></name></person-group><article-title>Transient hepatitis B surface antigenemia after neonatal hepatitis B immunization</article-title><source>Acta Paediatr</source><year>1996</year><volume>85</volume><issue>12</issue><fpage>1501</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">9001667</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodersen</surname><given-names>HP</given-names></name><name><surname>Beckers</surname><given-names>B</given-names></name><name><surname>Kohler</surname><given-names>H</given-names></name><name><surname>Dahlmanns</surname><given-names>C</given-names></name><name><surname>Kruska</surname><given-names>L</given-names></name><name><surname>Larbig</surname><given-names>D</given-names></name></person-group><article-title>The test for hepatitis B surface antigen is transiently positive after vaccination with recombinant vaccine</article-title><source>Nephrol Dial Transplant</source><year>1997</year><volume>12</volume><issue>12</issue><fpage>2756</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9430890</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otag</surname><given-names>F</given-names></name></person-group><article-title>False positive HBsAg result in blood donors due to administration of three different recombinant DNA Hepatitis B vaccines</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><issue>25-26</issue><fpage>3734</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12922105</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dow</surname><given-names>BC</given-names></name><name><surname>Yates</surname><given-names>P</given-names></name><name><surname>Galea</surname><given-names>G</given-names></name><name><surname>Munro</surname><given-names>H</given-names></name><name><surname>Buchanan</surname><given-names>I</given-names></name><name><surname>Ferguson</surname><given-names>K</given-names></name></person-group><article-title>Hepatitis B vaccinees may be mistaken for confirmed hepatitis B surface antigen-positive blood donors</article-title><source>Vox Sang</source><year>2002</year><volume>82</volume><issue>1</issue><fpage>15</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11856462</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katkov</surname><given-names>WN</given-names></name><name><surname>Ault</surname><given-names>MJ</given-names></name><name><surname>Dubin</surname><given-names>SB</given-names></name></person-group><article-title>Absence of hepatitis B surface antigenemia after vaccination</article-title><source>Arch Pathol Lab Med</source><year>1989</year><volume>113</volume><issue>11</issue><fpage>1290</fpage><pub-id pub-id-type="pmid">2530960</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janzen</surname><given-names>L</given-names></name><name><surname>Minuk</surname><given-names>GY</given-names></name><name><surname>Fast</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>KN</given-names></name></person-group><article-title>Vaccine-induced hepatitis B surface antigen positivity in adult hemodialysis patients: incidental and surveillance data</article-title><source>J Am Soc Nephrol</source><year>1996</year><volume>7</volume><issue>8</issue><fpage>1228</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">8866417</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanacker</surname><given-names>A</given-names></name><name><surname>Vandewiele</surname><given-names>I</given-names></name><name><surname>Verbanck</surname><given-names>J</given-names></name><name><surname>Schepkens</surname><given-names>H</given-names></name><name><surname>De Schoenmakere</surname><given-names>G</given-names></name><name><surname>De Laere</surname><given-names>E</given-names></name><name><surname>Maes</surname><given-names>B</given-names></name></person-group><article-title>Transiently positive hepatitis B surface antigen after vaccination with the new hepatitis B vaccine HBV-AS04</article-title><source>Am J Kidney Dis</source><year>2008</year><volume>52</volume><issue>5</issue><fpage>1028</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18971027</pub-id></element-citation></ref></ref-list></back></article>